Recombinant Human LDLR, C13&N15-labeled

• Cat.No.: LDLR-241H
• Product Overview: Recombinant Human LDLR MS Standard Protein, C13 and N15-labeled (LDLR, Heavy Labeled) Ala 22 - Arg 788 (Accession # NP_000518.1) was produced in human 293 cells (HEK293).

Specification

• Description: Low-Density Lipoprotein (LDL) Receptor, also known as LDLR, FH, FHC, LDLCQ2, and is a mosaic protein of ~840 amino acids (after removal of signal peptide) that mediates the endocytosis of cholesterol-rich LDL. It is a cell-surface receptor that recognizes the apoprotein B100 which is embedded in the phospholipid outer layer of LDL particles. The receptor also recognizes the apoE protein found in chylomicron remnants and VLDL remnants (IDL). [1] It belongs to the Low density lipoprotein receptor gene family.[2] LDL receptor complexes are present in clathrin-coated pits (or buds) on the cell surface, which when bound to LDL-cholesterol via adaptin, are pinched off to form clathrin-coated vesicles inside the cell. This allows LDL-cholesterol to be bound and internalized in a process known as endocytosis and prevents the LDL just diffusing around the membrane surface. This occurs in all nucleated cells (not erythrocytes), but mainly in the liver which removes ~70% of LDL from the circulation. Synthesis of receptors in the cell is regulated by the level of free intracellular cholesterol; if it is in excess for the needs of the cell then the transcription of the receptor gene will be inhibited. LDL receptors are translated by ribosomes on the endoplasmic reticulum and are modified by the Golgi apparatus before travelling in vesicles to the cell surface. LDL is directly involved in the development of atherosclerosis, due to accumulation of LDL-cholesterol in the blood. Atherosclerosis is the process responsible for the majority of cardiovascular diseases.[3-4]
• Source: HEK293
• Species: Human
• Form: Lyophilized from 0.22 μm filtered solution in PBS, pH7.4. Normally Mannitol or Trehalose are added as protectants before lyophilization.
• Molecular Mass: LDLR, Heavy Labeled, fused with 6×His tag at the C-terminus, has a calculated MW of 86 kDa. The predicted N-terminus is Ala22 or Asp193. DTT-reduced Protein migrates as 95-110 kDa &125-140 kDa due to glycosylation.
• Endotoxin: Less than 1.0 EU per μg of the LDLR, Heavy Labeled by the LAL method.
• Purity: >90% as determined by SDS-PAGE.
• Storage: Avoid repeated freeze-thaw cycles.No activity loss was observed after storage at:In lyophilized state for 1 year (4oC-8oC); After reconstitution under sterile conditions for 1 month (4oC-8oC) or 3 months (-20oC to -70oC).
• Tag: Non
• Protein length: Ala22-Arg788

Gene Information

• Gene Name: LDLR low density lipoprotein receptor [ Homo sapiens ]
• Official Symbol: LDLR
• Synonyms: LDLR; low density lipoprotein receptor; low-density lipoprotein receptor; familial hypercholesterolemia; LDL receptor; low-density lipoprotein receptor class A domain-containing protein 3; FH; FHC; LDLCQ2
• Gene ID: 3949
• mRNA Refseq: NM_000527
• Protein Refseq: NP_000518
• MIM: 606945
• UniProt ID: P01130
• Chromosome Location: 19p13.2
• Pathway: Bile secretion, organism-specific biosystem; Bile secretion, conserved biosystem; Chylomicron-mediated lipid transport, organism-specific biosystem; DNA damage response (only ATM dependent), organism-specific biosystem; Endocytosis, organism-specific biosystem; Endocytosis, conserved biosystem; Hepatitis C, organism-specific biosystem
• Function: calcium ion binding; glycoprotein binding; low-density lipoprotein receptor activity; protein binding; receptor activity; very-low-density lipoprotein particle receptor activity

Reviews

08/11/2020

The LDLR protein stands out for its exceptional quality, making it an excellent choice to meet my experimental requirements.

10/07/2018

Its purity and consistency guarantee reliable and reproducible results, ensuring the reliability of my research outcomes.

03/04/2017

the LDLR protein offers superior quality and reliability, making it a perfect fit for my experimental needs.

Q&As

Are there conditions where upregulation of LDLR might be beneficial?

Yes, conditions where increasing the expression or function of LDLR could potentially aid in reducing circulating LDL cholesterol and minimizing cardiovascular risk.

Are there ongoing research efforts regarding LDLR and its clinical applications?

Yes, research is continually conducted to better understand LDLR-related conditions and to develop more effective treatments, including gene-editing technologies and novel therapies.

What are the clinical implications of LDLR dysfunction?

Dysfunction in LDLR can lead to high levels of LDL cholesterol in the blood, contributing to conditions like familial hypercholesterolemia and an increased risk of heart disease.

How does LDLR impact atherosclerosis?

A dysfunctional LDLR can lead to an accumulation of LDL cholesterol in the arteries, promoting atherosclerosis, the hardening and narrowing of arteries.

What treatment options exist for LDLR-related conditions?

Treatments involve lifestyle changes, cholesterol-lowering medications, and in some cases, gene therapies or specialized medications targeting the LDL receptor.